To date 34 of 306 (11%) myeloma patients analysed by whole genome or exome sequencing studies have been found to have missense mutations in DIS3 that may be functionally relevant (Figure 6) [25,26,27,28]. The gene discussed is DIS3; the disease is plasma cell myeloma.